financetom
Business
financetom
/
Business
/
Whitecap Sees Production at High End of Guidance as its Receives Investment-Grade Rating
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Whitecap Sees Production at High End of Guidance as its Receives Investment-Grade Rating
Sep 19, 2024 6:19 AM

08:32 AM EDT, 09/19/2024 (MT Newswires) -- Whitecap Resources ( SPGYF ) on Thursday said it expects 2024 production will be at the high end of its guidance.

The company also said it received an investment-grade credit rating from DBRS after adding a $2 billion debt facility.

The Western Canadian oil and gas producer said it expects its output to be near 172,000 barrels of oil equivalent per day, the upper end of its 2024 guidance, as it expands its operations with new wells in the Montney and Duvernay fields in Alberta and British Columbia.

The company received an investment-grade BBB (Low) rating from DBRS. The debt facility replaces Whitecap's existing secured credit and term loan facilities.

Though unsecured, the covenants on the credit facility call for Whitecap to meet a number of financial ratios, including keeping debt at less than four times its EBITDA. The company said it currently has a debt to EBITDA ratio of 0.6 times.

"The New Facility along with our investment grade credit rating allows us to access the investment grade bond market to diversify our debt structure into a deeper market that provides for longer tenors and a lower cost of funding for Whitecap. We view the investment grade bond market as an important part of our capital structure going forward," the company said

Whitecap shares closed up $0.01 to $10.33 Wednesday on the Toronto Stock Exchange.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation
Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation
May 24, 2024
08:17 AM EDT, 05/24/2024 (MT Newswires) -- Organon (OGN) and Shanghai Henlius Biotech said Friday their marketing authorization applications for HLX14, a denosumab biosimilar, have been validated by the European Medicines Agency. The submissions were based on a phase 3 study comparing HLX14 with denosumab in postmenopausal women with osteoporosis, the companies said. Henlius licensed HLX14 to Organon in 2022...
--Cato Keeps Quarterly Dividend at $0.17 per share, Payable June 24 to Shareholders of Record June 10
--Cato Keeps Quarterly Dividend at $0.17 per share, Payable June 24 to Shareholders of Record June 10
May 24, 2024
08:17 AM EDT, 05/24/2024 (MT Newswires) -- Price: 5.73, Change: -0.05, Percent Change: -0.87 ...
E3 Lithium Narrows Q1 Loss; Company Hasn't Started Commercial Production or Generated Cash Flow
E3 Lithium Narrows Q1 Loss; Company Hasn't Started Commercial Production or Generated Cash Flow
May 24, 2024
08:25 AM EDT, 05/24/2024 (MT Newswires) -- E3 Lithium ( EEMMF ) on Friday reported a narrower loss for the first quarter even though the company has not generated revenues from operations and had an accumulated deficit of $45.2 million at the end of March. The company reported a first-quarter net loss of $2.4 million, or $0.03 per share, compared...
Verastem Reports Results of Potential Pancreatic Cancer Treatment, Submits Rolling New Drug Application for Rare Ovarian Cancer
Verastem Reports Results of Potential Pancreatic Cancer Treatment, Submits Rolling New Drug Application for Rare Ovarian Cancer
May 24, 2024
08:25 AM EDT, 05/24/2024 (MT Newswires) -- Verastem Oncology (VSTM) late Thursday reported that an ongoing phase 1/2 clinical trial evaluating avutometinib and defactinib in combination with gemcitabine and nab-paclitaxel in 41 patients with metastatic pancreatic cancer reached an interim partial response rate of 83%. Of 26 patients in all the trial cohorts who have had their first scan while...
Copyright 2023-2025 - www.financetom.com All Rights Reserved